Key result
Clopidogrel resistance is driven by CYP2C19 polymorphisms, epigenetic regulators, drug interactions, and clinical comorbidities.
Why the study?
Clopidogrel resistance limits therapeutic efficacy and increases adverse cerebrocardiovascular outcomes, making an understanding of underlying mechanisms essential for optimizing treatment.
Design
Review
Authors
Loading...
Promotes caution with clopidogrel in cerebrocardiovascular prevention; leaves open personalized strategies to address its multifactorial resistance.
Understanding the genetic, epigenetic, and pharmacological mechanisms of clopidogrel resistance is crucial for optimizing antiplatelet therapy and improving cardiovascular outcomes.
Xinyi Huang (2026) conducted a review in Clopidogrel resistance. Clopidogrel was evaluated. Clopidogrel resistance is driven by multifactorial mechanisms including genetic factors like CYP2C19 polymorphisms, epigenetic regulators, drug-drug interactions, and clinical comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: